ArticleThe Journal of biological chemistry2026
Hepatic management of toxic sterols after acute deletion of Cyp51 from cholesterol synthesis.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lanosterol 14α-demethylase (CYP51), a key enzyme in cholesterol synthesis, is essential for normal liver function. Reduced CYP51 activity leads to metabolism-associated liver disease and ultimately hepatocellular carcinoma, yet the hepatocellular processes most affected and their crosstalk with other liver cell types remain poorly defined. Here, we present a new inducible liver-specific Cyp51 KO mouse (iLKO) model designed to study how acute disruption of cholesterol synthesis is managed in the adult liver. Doxycycline-inducible deletion minimizes developmental confounders of albumin-Cre models and enables isolation of viable primary hepatocytes. iLKO hepatocytes and liver tissue showed efficient CYP51 depletion with marked accumulation of lanosterol and 24,25-dihydrolanosterol, whereas hepatic cholesterol levels remained unchanged or only mildly reduced, indicating compensatory uptake and/or pathway rerouting. Histology and transmission electron microscopy revealed hepatomegaly with mild portal inflammation, ductular reaction, endoplasmic reticulum dilation, mitochondrial swelling, and increased nuclear lipid droplets, consistent with adaptation to endoplasmic reticulum stress but without overt fibrosis at the studied time points. Notably, crystal-like inclusions-particularly in Kupffer cells-were observed. Although MALDI-TOF mass spectrometry imaging could not determine their exact composition, their presence in the context of toxic sterol overload strongly suggests noncholesterol sterol crystallization as a previously unrecognized trigger of inflammation. In summary, the iLKO model allows dissection of sterol toxicity independently of developmental effects and provides mechanistic insight into how disrupted cholesterol synthesis in adult hepatocytes initiates sterol-driven cellular stress and inflammation that predispose to metabolism-associated liver disease and hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.